|
Authors:
OukkasS, allaliA, yahyaouiH, aitameurM, chakour M, Morocco
|
|
Abstract:
(HNF) and low molecular weight heparins, used for biological monitoring of heparin-like anticoagulant therapy. This work aims to show the quality of heparin management thanks to the biological monitoring by anti-Xa activity in 10 cases. The average age of our cases was 58.9 years with a frequency peak between 55 and 57 years (40%) and a clear male predominance. The most common clinical entity was the recurrence of deep vein thrombosis of the lower limbs, which was present in 40% of cases with inpatient management in the cardiology department. Our patients had all undergone heparin treatment according to the indications in force, but because of its better benefit / risk contribution the LMWH administered rate exceeded that of the UFH (70% against only 30% UFH). The activated partial thromboplastin time (APTT) value is either insufficiently prolonged for 25% of patients with UFH, or inconclusive during LMWH treatment because TCA is the almost exclusive reflection of anti-IIa activity (antithrombin). ). It is for this reason that biological monitoring by measurement of anti-Xa activity is necessary and justified to ensure effective anticoagulation in targeted therapeutic areas without failing to signal the occurrence of induced thrombocytopenia. by heparin or overdose.
|
